If you have any problems in viewing this Newsletter, please click here
 
17.07.2018
     
Molecular Pathology
 
Antibodies engineered to deliver consistent, specific and sensitive stains for confident diagnosis
IDH1 R132H antibody: GenomeMe vs. Dianova
IDH1 R132H is becoming an important marker for Glioma diagnosis. Compared to the existing H09 clone, IHC132 clone has significantly better specificity with less background staining, offering superior quality and staining confidence on Glioma tissues.
 
 
 
IDH1 point mutation tumor tissue:
Antibody [Clone]:
Optimal dilution:
1:200
Normal TMA:
All negative
Glioma TMA:
4/14 positive (28.57%)
Astrocytoma TMA:
10/36 positive (27.88%)
IDH1 point mutation tumor tissue:
3/3 positive (2 images are shown beside)
 
 
 
Antibody [Clone]:
IDH1 R132H [H09]
Optimal dilution:
1:100
Normal TMA:
All negative
Glioma TMA:
2/14 positive (14.29%)
Astrocytoma TMA:
8/36 positive (22.22%)
IDH1 point mutation tumor tissue:
3/3 positive (2 images are shown beside)
 
 
Conclusion: IDH1 R132H antibody from GenomeMe shows higher sensitivity
 
 
MMR/MSI Panel Launch: MSH2, MSH6, MLH1, and PMS2 antibodies 
Mouse monoclonal GeneAb™ MSH2 [IHC410] on Esophagus.
Mouse monoclonal GeneAb™ MSH6 [IHC006] on Esophagus.
Mouse monoclonal GeneAb™ MLH1 [IHC409] on Esophagus.
Mouse monoclonal GeneAb™ PMS2 [IHC412] on Duodenum.
  
 
Email: lucerna-chem@lucerna-chem.ch Phone: +41 41 420 96 36 Fax: +41 41 420 96 56 Web: www.lucerna-chem.ch
 Lucerna-Chem,  AG Abendweg 18,  CH-6006 Luzern

Lucerna-Chem respects the web and the privacy of those who use it. We do not rent or sell our mailing list to anyone.
This e-Mail is Virus checked!

If you'd rather not receive Emails about product updates or Newsletters, click HERE.